New pill aims to silence stubborn chronic cough
NCT ID NCT07671924
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new extended-release tablet called nalbuphine for people with refractory chronic cough—a cough that persists despite treatment. About 100 adults will receive either the drug or a placebo for 6 weeks. The main goal is to see if the drug reduces how often people cough over 24 hours.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nalbuphine extended-release tablets
What this could lead to
If successful, this could provide a new treatment option for people with chronic cough that doesn't respond to other therapies.
What could go wrong
This is an early Phase 2 trial with only 100 participants, so results may not be conclusive. The drug may not reduce cough better than placebo, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY CHRONIC COUGH are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••